Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Risk factors for contrast induced nephropathy: a study among Italian patients.

Evola S, Lunetta M, Macaione F, Fonte G, Milana G, Corrado E, Bonura F, Novo G, Hoffmann E, Novo S.

Indian Heart J. 2012 Sep-Oct;64(5):484-91. doi: 10.1016/j.ihj.2012.07.007. Epub 2012 Jul 27.

2.

Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.

Kurtul A, Yarlioglues M, Murat SN, Demircelik MB, Acikgoz SK, Ergun G, Duran M, Cetin M, Ornek E.

Angiology. 2015 May;66(5):433-40. doi: 10.1177/0003319714535238. Epub 2014 May 16.

PMID:
24834929
3.

Association between N-terminal pro-brain natriuretic peptide levels and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.

Kurtul A, Duran M, Yarlioglues M, Murat SN, Demircelik MB, Ergun G, Acikgoz SK, Sensoy B, Cetin M, Ornek E.

Clin Cardiol. 2014 Aug;37(8):485-92. doi: 10.1002/clc.22291. Epub 2014 May 7.

4.

Contrast medium volume to creatinine clearance ratio: a predictor of contrast-induced nephropathy in the first 72 hours following percutaneous coronary intervention.

Tan N, Liu Y, Zhou YL, He PC, Yang JQ, Luo JF, Chen JY.

Catheter Cardiovasc Interv. 2012 Jan 1;79(1):70-5. doi: 10.1002/ccd.23048. Epub 2011 Oct 11. Erratum in: Catheter Cardiovasc Interv. 2013 Jun 1;81(7):1256-7.

PMID:
21990069
5.

Predictive factors of contrast-induced nephropathy in patients undergoing primary coronary angioplasty.

Ivanes F, Isorni MA, Halimi JM, Fauchier L, Saint Etienne C, Babuty D, Angoulvant D, Brunet-Bernard A.

Arch Cardiovasc Dis. 2014 Aug-Sep;107(8-9):424-32. doi: 10.1016/j.acvd.2014.05.008. Epub 2014 Jul 28.

6.

Insulin Resistance Increases the Risk of Contrast-Induced Nephropathy in Patients Undergoing Elective Coronary Intervention.

Li Y, Liu Y, Shi D, Yang L, Liang J, Zhou Y.

Angiology. 2016 Feb;67(2):139-45. doi: 10.1177/0003319715578997. Epub 2015 Apr 5.

PMID:
25843952
7.

Volume-to-creatinine clearance ratio in patients undergoing coronary angiography with or without percutaneous coronary intervention: implications of varying definitions of contrast-induced nephropathy.

Capodanno D, Ministeri M, Cumbo S, Dalessandro V, Tamburino C.

Catheter Cardiovasc Interv. 2014 May 1;83(6):907-12. doi: 10.1002/ccd.25153. Epub 2013 Aug 31.

PMID:
23934631
8.

ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy.

Umruddin Z, Moe K, Superdock K.

J Nephrol. 2012 Sep-Oct;25(5):776-81. doi: 10.5301/jn.5000059.

PMID:
22322819
9.

Circulating tumour necrosis factor receptors 1 and 2 predict contrast-induced nephropathy and progressive renal dysfunction: a prospective cohort study.

An JN, Yoo KD, Hwang JH, Kim HL, Kim SH, Yang SH, Kim JH, Kim DK, Oh YK, Kim YS, Lim CS, Lee JP.

Nephrology (Carlton). 2015 Aug;20(8):552-9. doi: 10.1111/nep.12448.

PMID:
25783484
10.

[Association between high-sensitivity C-reactive protein and contrast-induced nephropathy after primary percutaneous coronary intervention].

He YT, Tan N, Liu YH, Chen SQ, Liu Y, Huang SJ, Yang DH, Ye P, Ran P.

Zhonghua Xin Xue Guan Bing Za Zhi. 2013 May;41(5):394-8. Chinese.

PMID:
24021122
11.

Contrast between innovator drug- and generic drug-induced renal dysfunction on coronary angiography (CONTRAST study).

Nakamura A, Miura S, Sugihara M, Miyase Y, Norimatsu K, Shiga Y, Nishikawa H, Saku K.

Heart Vessels. 2014 Sep;29(5):603-10. doi: 10.1007/s00380-013-0410-6. Epub 2013 Sep 27.

PMID:
24072136
12.

Impact of automated contrast injector systems on contrast use and contrast-associated complications in patients undergoing percutaneous coronary interventions.

Gurm HS, Smith D, Share D, Wohns D, Collins J, Madala M, Koneru S, Menees D, Chetcuti S.

JACC Cardiovasc Interv. 2013 Apr;6(4):399-405. doi: 10.1016/j.jcin.2012.11.008. Epub 2013 Mar 20.

13.

Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.

Kandula P, Shah R, Singh N, Markwell SJ, Bhensdadia N, Navaneethan SD.

Nephrology (Carlton). 2010 Mar;15(2):165-70. doi: 10.1111/j.1440-1797.2009.01204.x.

PMID:
20470274
14.

[Risk factors of contrast-induced nephropathy in patients after coronary artery intervention].

Zhao YY, Liu DW, Wang JS, Ouyang J, Zhang WZ, Zhang WJ, Meng JQ, Tang JM.

Zhonghua Yi Xue Za Zhi. 2012 Jun 12;92(22):1547-9. Chinese.

PMID:
22944059
15.

Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study.

Barbieri L, Verdoia M, Schaffer A, Niccoli G, Perrone-Filardi P, Bellomo G, Marino P, Suryapranata H, Luca GD.

Angiology. 2015 Apr;66(4):333-8. doi: 10.1177/0003319714533401. Epub 2014 May 15.

PMID:
24830422
16.

Frequency and risk factors of contrast-induced nephropathy after cardiac catheterization in type II diabetic patients: a study among Egyptian patients.

Sany D, Refaat H, Elshahawy Y, Mohab A, Ezzat H.

Ren Fail. 2014 Mar;36(2):191-7. doi: 10.3109/0886022X.2013.843400. Epub 2013 Oct 21.

PMID:
24138570
17.

Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.

Barbieri L, Verdoia M, Schaffer A, Cassetti E, Marino P, Suryapranata H, De Luca G; Novara Atherosclerosis Study Group (NAS)..

Nutr Metab Cardiovasc Dis. 2015 Feb;25(2):181-6. doi: 10.1016/j.numecd.2014.08.008. Epub 2014 Sep 19.

PMID:
25315668
18.

Platelet-to-Lymphocyte Ratio Predicts Contrast-Induced Nephropathy in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.

Kocas C, Yildiz A, Abaci O, Karaca OS, Firdin N, Dalgic Y, Bostan C, Ersanli M.

Angiology. 2015 Nov;66(10):964-8. doi: 10.1177/0003319715578057. Epub 2015 Apr 7.

PMID:
25852211
19.

Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.

Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE.

Am Heart J. 2003 Dec;146(6):E23.

PMID:
14661012
20.

Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.

CalabrĂ² P, Bianchi R, Caprile M, Sordelli C, Cappelli Bigazzi M, Palmieri R, Gigantino G, Limongelli G, Capozzi G, Cuomo S, CalabrĂ² R.

Minerva Cardioangiol. 2010 Feb;58(1):35-40.

PMID:
20145594

Supplemental Content

Support Center